Yiling Pharmaceuticals: Application for clinical trials of the innovative drug G201-Na capsules approved.

On July 7, 2025, Yiling Pharmaceutical announced that the company had received the "Clinical Trial Approval Notice for Drugs" issued by the National Medical Products Administration. The clinical trial application for G201-Na capsules has been approved. G201-Na capsules are small molecule gonadotropin-releasing hormone receptor antagonists used in assisted reproductive technology to control patients undergoing controlled ovarian hyperstimulation therapy and prevent premature ovulation.